The Additional Value of Somatostatin Receptor Positron Emission Computed Tomography ([ 68 Ga]Ga-DOTATOC PET/CT) Compared with Magnetic Resonance Imaging of the Head and Neck Region in Paraganglioma Patients: A Pilot Study
The Dutch guideline for patients suspected of head and neck paragangliomas (HNPGLs) recommends magnetic resonance imaging (MRI) and/or computed tomography (CT) of the head and neck area. Additionally, it suggests considering additional nuclear imaging. The aim of this study was to evaluate the outco...
Gespeichert in:
Veröffentlicht in: | Cancers 2024-02, Vol.16 (5), p.986 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The Dutch guideline for patients suspected of head and neck paragangliomas (HNPGLs) recommends magnetic resonance imaging (MRI) and/or computed tomography (CT) of the head and neck area. Additionally, it suggests considering additional nuclear imaging. The aim of this study was to evaluate the outcomes of [
Ga]Ga-DOTATOC PET/CT compared to MRI in patients with suspected HNPGLs and carriers of genetic variations.
In this single-center pilot study, retrospective data were obtained from consecutive patients between 2016 and 2023. Both MRI and [
Ga]Ga-DOTATOC PET/CT were performed within 12 months. The primary outcome was the location of HNPGLs.
A total of 25 consecutive patients were included, and 7 patients (28.0%,
= 0.5) showed differences between the imaging modalities, of whom 5 patients had unexpected localizations with additional uptake by somatostatin receptors (SSTR) on the [
Ga]Ga-DOTATOC PET/CT.
The authors recommend performing baseline imaging with [
Ga]Ga-DOTATOC PET/CT (if available) in variant carriers and using MRI/CT for follow-up according to the regional protocol, thereby shifting the gold standard for baseline imaging from MRI/CT to [
Ga]Ga-DOTATOC PET/CT. |
---|---|
ISSN: | 2072-6694 2072-6694 |
DOI: | 10.3390/cancers16050986 |